Literature DB >> 10679255

Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum.

C S Lin1, A Lau, R Tu, T F Lue.   

Abstract

Inhibition of cGMP-specific phosphodiesterase type V (PDE5) has been shown to improve penile erection in patients with erectile dysfunction. We report here the cloning of three PDE5 isoforms from human penile tissues. Two of the isoforms were identical to PDE5A1 and PDE5A2, respectively, which had been isolated from nonpenile tissues. The third isoform was novel and hence called PDE5A3. The deduced amino acid sequence of PDE5A3 was the same as the C-terminal 823-residue sequence of PDE5A1 and PDE5A2. While PDE5A1 and A2 isoforms were expressed in all tissues examined, the A3 isoform was confined to tissues with a smooth muscle or cardiac muscle component. When expressed in COS-7 cells, PDE5A1, A2, and A3 isoforms had similar cGMP-catalytic activities with K(m) of 6.2, 5.75, and 6.06 microM, respectively. Their cGMP-catalytic activities were inhibited by zaprinast with IC(50) values of 3.2 microM, 1.3 microM, and 1.6 microM, respectively, and by sildenafil with IC(50) of 28, 14, and 13 nM, respectively. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10679255     DOI: 10.1006/bbrc.2000.2187

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  32 in total

Review 1.  NO as a signalling molecule in the nervous system.

Authors:  Juan V Esplugues
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle.

Authors:  K S Murthy
Journal:  Biochem J       Date:  2001-11-15       Impact factor: 3.857

3.  Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.

Authors:  Fiona Murray; Margaret R MacLean; Nigel J Pyne
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 4.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

5.  Effect of berberine on the mRNA expression of nitric oxide synthase (NOS) in rat corpus cavernosum.

Authors:  Yan Tan; Zhangyin Ming; Qiang Tang; Zhaojian Jiang; Benrong Hu; Jizhou Xiang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

6.  Pharmacologic treatment of erectile dysfunction.

Authors:  William D Steers
Journal:  Rev Urol       Date:  2002

7.  Evolutionary conservation of alternative splicing in chicken.

Authors:  S Katyal; Z Gao; R-Z Liu; R Godbout
Journal:  Cytogenet Genome Res       Date:  2007       Impact factor: 1.636

8.  Phosphodiesterase type 5 and high altitude pulmonary hypertension.

Authors:  A A Aldashev; B K Kojonazarov; T A Amatov; T M Sooronbaev; M M Mirrakhimov; N W Morrell; J Wharton; M R Wilkins
Journal:  Thorax       Date:  2005-08       Impact factor: 9.139

9.  Pharmacological postconditioning by bolus injection of phosphodiesterase-5 inhibitors vardenafil and sildenafil.

Authors:  Bernd Ebner; Annette Ebner; Anna Reetz; Stefanie Böhme; Antje Schauer; Ruth H Strasser; Christof Weinbrenner
Journal:  Mol Cell Biochem       Date:  2013-03-27       Impact factor: 3.396

Review 10.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.